Education
About Us
Working with TipRanks
Follow Us
Aim Immunotech Inc. (AIMI)
:AIMI
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-8Last Year’s EPS
-3Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: -22.22%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant clinical and strategic advancements, including new studies, leadership expansion, and cost reductions. However, financial challenges were noted, with low cash reserves and a risk of delisting from the stock exchange, which the company is actively working to address.Company Guidance
During the AIM ImmunoTech Fourth Quarter and Full Year 2024 Update Conference Call, CEO Thomas Equels provided extensive guidance on the company's progress and future plans. Key clinical updates included the continuation into Phase 2 of the DURIPANC trial evaluating Ampligen with AstraZeneca's Imfinzi for metastatic pancreatic cancer, and the completion of the AMP-518 study on post-COVID conditions. Financial metrics revealed that research and development expenses decreased to $6.2 million from $10.9 million the previous year, while general and administrative expenses fell to $13.7 million from $21.1 million. The company held approximately $4 million in cash and equivalents as of December 31, 2024. Strategic initiatives to maintain NYSE American listing, including a potential reverse stock split, were also discussed. The call concluded with a commitment to advancing Ampligen's potential across several high-need medical areas.New Clinical Study with AstraZeneca
AIM ImmunoTech announced plans to conduct a new clinical study evaluating Ampligen in combination with AstraZeneca's intranasal influenza vaccine, FluMist, for influenza, including avian flu.
Leadership Expansion
The company strengthened its leadership with the addition of two Board members, Ted Kellner and David Chemerow, bringing extensive investment and financial expertise.
Approval for Phase 2 Pancreatic Cancer Trial
Continuation into the Phase 2 portion of the DURIPANC pancreatic cancer trial has been approved, with dosing commenced, marking a key advancement in this program.
Publication and Patent Advancements
A new U.S. patent was granted for the treatment of endometriosis, and a Netherlands patent for post-COVID fatigue. Also, new data was published from a study in early-stage triple negative breast cancer.
R&D Cost Reduction
Research and development expenses decreased from $10.9 million in 2023 to $6.2 million in 2024, indicating more efficient use of resources.
G&A Expenses Reduction
General and administrative expenses decreased from $21.1 million in 2023 to $13.7 million in 2024, reflecting improved operational efficiency.
AIMI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AIMI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $0.09 | $0.09 | 0.00% |
Mar 27, 2025 | $0.13 | $0.13 | 0.00% |
Nov 15, 2024 | $0.25 | $0.22 | -12.00% |
Aug 16, 2024 | $0.29 | $0.30 | +3.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Aim Immunotech Inc. (AIMI) report earnings?
Aim Immunotech Inc. (AIMI) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is Aim Immunotech Inc. (AIMI) earnings time?
Aim Immunotech Inc. (AIMI) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AIMI EPS forecast?
AIMI EPS forecast for the fiscal quarter 2025 (Q2) is -8.